This article is a narrative review, meaning it summarizes existing ideas rather than reporting new patient data. It explores the concept that cardiovascular disease involves immune, metabolic, and inflammatory processes working together. This perspective could help doctors better assess risk and tailor prevention strategies for individual patients.
The text notes that ongoing immune dysregulation and chronic low-grade inflammation actively drive the progression of atherosclerosis. Because this is a review, it does not include specific numbers on how many people were studied or which specific drugs were tested in trials. Instead, it highlights medications like GLP-1 receptor agonists, SGLT2 inhibitors, and immune checkpoint inhibitors as areas of interest.
Readers should understand that this information is conceptual and does not replace clinical trial evidence. While the idea of treating heart disease as a systemic inflammatory condition is promising, more research is needed to confirm these strategies in real-world settings. Patients should not change medications based on this review alone.